Patents Assigned to Gryphon Therapeutics
-
Patent number: 7094871Abstract: The present invention provides methods, apparatus and kits for synthesizing assembled peptides and proteins on a solid phase with sequential ligation of three or more unprotected peptide segments using chemoselective and mild ligation chemistries in aqueous solution. Also provided are methods of monitoring solid phase sequential ligation reactions using MALDI or electrospray ionization mass spectrometry of reaction products.Type: GrantFiled: November 15, 2001Date of Patent: August 22, 2006Assignee: Gryphon TherapeuticsInventors: Lynne Canne, Stephen B. H. Kent, Reyna Simon
-
Patent number: 7030218Abstract: The present invention concerns methods and compositions for extending the technique of native chemical ligation of a wider range of peptides, polypeptides, other polymers and other molecules via an amide bond (see FIG. 1). The invention further provides methods and uses for such proteins and derivatized proteins. The invention is particularly suitable for use in the synthesis of optionally polymer-modified, synthetic bioactive proteins, and of pharmaceutical compositions that contain such proteins.Type: GrantFiled: July 12, 2001Date of Patent: April 18, 2006Assignee: Gryphon TherapeuticsInventors: Christie L. Hunter, Paolo Botti, James A. Bradburne, Shiah-yun Chen, Sonya Cressman, Stephen B. H. Kent, Gerd G. Kochendoerfer, Donald W. Low
-
Patent number: 7030217Abstract: The present invention provides methods, apparatus and kits for synthesizing assembled peptides and proteins on a solid phase with sequential ligation of three or more unprotected peptide segments using chemoselective and mild ligation chemistries in aqueous solution. Also provided are methods of monitoring solid phase sequential ligation reactions using MALDI or electrospray ionization mass spectrometry of reaction products.Type: GrantFiled: November 15, 2001Date of Patent: April 18, 2006Assignee: Gryphon Therapeutics, Inc.Inventors: Lynne Canne, Stephen B. H. Kent, Reyna Simon
-
Patent number: 6977292Abstract: The invention is directed to nucleophile-stable thioester generating compounds comprising a carboxyester thiol. The compounds have wide applicability in organic synthesis, including the generation of peptide-, polypeptide- and other polymer-thioesters. The invention is particularly useful for generating activated-thioesters from precursors that are made under conditions in which strong nucleophiles are employed, such as peptides or polypeptides made using Fmoc SPPS, as well as multi-step ligation or conjugation schemes that require (or benefit from the use of) compatible selective approaches for directing a specific ligation or conjugation reaction of interest.Type: GrantFiled: August 30, 2001Date of Patent: December 20, 2005Assignee: Gryphon TherapeuticsInventors: Paolo Botti, James A. Bradburne, Stephen B. H. Kent
-
Patent number: 6942852Abstract: N-terminally modified RANTES derivatives are disclosed. The derivatives effectively block the inflammatory effects of RANTES, and are useful for the treatment of asthma, allergic rhinitis, atopic dermatitis, atheroma/atherosclerosis, and rheumatoid arthritis. Additionally, the compounds are useful for the treatment of HIV infection.Type: GrantFiled: October 4, 2000Date of Patent: September 13, 2005Assignee: Gryphon Therapeutics, Inc.Inventors: Robin E. Offord, Darren Thompson, Jill Wilken
-
Patent number: 6844161Abstract: Novel proteins and protein libraries are disclosed. The proteins possess one or more functional protein modules from different parent protein molecules. The proteins and protein libraries are exemplified by the preparation of cross-over chemokines that contain various combinations of peptide segments derived from RANTES, SDS-1 and vMIP-I and to vMIP-II. The proteins and libraries are extremely pure and can be provided in non-limiting high yields suitable for diagnostic and high-throughput screening assays.Type: GrantFiled: August 31, 1998Date of Patent: January 18, 2005Assignee: Gryphon Therapeutics, Inc.Inventors: Michael A. Siani, Jill Wilken, Reyna Simon, Stephen B. H. Kent
-
Patent number: 6673347Abstract: Protein and polypeptide derivatives and their salts are claimed characterized in that a protein or polypeptide is conjugated via an intermediate grouping containing at least one radical of the formula —C(R)═N— (or —N═C(R)—) or —CH(R)—NH— (or —NH—CH(R)—), wherein R is hydrogen or a hydrocarbon residue which may be substituted, with the same or a different protein or polypeptide, with a reporter group or a cytotoxic agent as well as a process for their preparation and the novel intermediates therefor.Type: GrantFiled: May 12, 1994Date of Patent: January 6, 2004Assignee: Gryphon TherapeuticsInventors: Robin Ewart Offord, Keith Rose
-
Patent number: 6663869Abstract: A homogeneous polyoxime composition is provided, in which the polyoxime molecules present comprise a first organic baseplate molecule, which is a polypeptide, wherein the baseplate molecule is linked to at least two second organic molecules, which may be the same or different from one another. In the compositions, the linkages between the baseplate and said organic molecules are oxime linkages formed by reaction of an orthogonal reactive group on each the organic molecules with a complementary orthogonal reactive group on the baseplate.Type: GrantFiled: August 4, 2000Date of Patent: December 16, 2003Assignee: Gryphon Therapeutics, Inc.Inventors: Keith Rose, Robin E. Offord
-
Patent number: 6552167Abstract: Provided are chains of precise length and methods for their preparation. These chains are formed by the reaction of a derivative of a diacid and a diamine in a stepwise manner on a support. One of the reactants contains a water soluble oligomer, preferably polyethylene glycol. These chains are then used to chemically modify target macromolecules such as biologically important polypeptides.Type: GrantFiled: August 23, 1999Date of Patent: April 22, 2003Assignee: Gryphon Therapeutics, Inc.Inventor: Keith Rose